Researcher’s Profile

1
Top Doctor: 
1

Joseph G. Jurcic, MD

Director, Hematologic Malignancies Section
Body: 

Dr. Joseph Jurcic is Professor of Medicine at Columbia University Medical Center and Director of the Hematologic Malignancies Section of the Division of Hematology/Oncology. His main focus is the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. Research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, the development of novel small molecule inhibitors for leukemia, and the molecular monitoring of minimal residual disease.

He is the 2001 recipient of the Louis and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research from Memorial Sloan-Kettering Cancer Center. He is author or coauthor of more than 80 articles and book chapters, has been the principal investigator on over 25 clinical trials, and regularly lectures at national and international meetings. He serves as a Leukemia Section Editor for The Oncologist. Prior to joining the faculty at Columbia University Medical Center, he was an Attending Physician on the Leukemia Service at Memorial Sloan-Kettering Cancer Center for over 18 years.

Publications: 

Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr. Prognostic significance of minimal residual disease detection and PML/RAR-a isoform type: Long-term follow-up in acute promyelocytic leukemia.  Blood 2001; 98:2651-2656.

Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud ÅM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA.  Targeted alpha particle immunotherapy for myeloid leukemia.  Blood 2002; 100:1233-1239.

Aliff TB, Maslak PB, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA.  Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.  Cancer 2003; 97:1025-1032.

Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, Jurcic J, Velez-Garcia E, Seiter K, Scheinberg DA, Levitt D, Wedel N.  Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.  Leukemia 2003; 17:314-318.

Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas K, Finn RD, Larson SM, O’Reilly RJ, Scheinberg DA, Jurcic JG.  Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.  Bone Marrow Transplant 2003; 32:549-556.